Biotech firm Metis plans Hong Kong IPO
Hangzhou-based Metis Pharmaceuticals is considering a Hong Kong IPO to raise up to USD 200 million, according to sources. The AI-driven drug discovery firm has raised USD 300 million to date and counts CICC Capital and HongShan among its key investors.